PLX101D is a high frequency mobile flat-panel digital X-ray radiography system, suitable for radiology, orthopedics, ward, emergency room, operating room, ICU and other places. With flexible movement, easy operation, high efficiency, to meet the human body's head, limbs, chest, spine, lumbar vertebrae, abdomen, etc. 1. Generator output: 5.0 kW.

X-ray Machine – Mobile (16/32/63/100mA)-PLX-100BY SKU: CM000502 Categories: Diagnostic Imaging , Medical Equipment , Radiology Tags: High Frequency , Mobile , X-RAY Description

Price was changed recently, so please send us email to [email protected] that we could provide you with update price information. This product was added to our catalog on Saturday 07 April, 2012.

Built-in battery: With a built-in back up battery to enable taking 200 to 500 pictures after power interruption. Rotary pillar.

PLX-100 is an investigational therapy being developed by Polaryx Therapeutics to treat Batten disease, the most common form of neuronal ceroid lipofuscinoses (NCLs), a group of neurodegenerative disorders caused by mutations in one of 14 genes.

• Our high frequency technology assures the best image in every operating condition along with reduced patient dose and extended x-ray tube life time . • The generator provide the right …

With kV, mAs two button adjustment, LCD display, multifunction of safety guard. With 50 preset exposure programs, and can be modified and stored by the user for convenient operation. With a high-quality knockdown X-ray generator to reduce irradiation, it …

Polaryx has a diversified potentially disease-modifying pipeline composed of small molecule and gene therapies. PLX-100 is a combination of PLX-200 and a supplement. The safety of each component has been well established.

PLX101 High Frequency Mobile X-ray Equipment offered by China manufacturer Jiangsu Rooe Medical Technology Co., Ltd.. Buy PLX101 High Frequency Mobile X-ray Equipment directly with low price and high quality.

Dec 12, 2017 · Polaryx Therapeutics ’ investigative drug PLX-100 has been granted orphan drug designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of neuronal ceroid lipofuscinosis (NCL), also known as Batten disease.